HIPRA has extended the presence of VIMCO® (vaccine for the prevention of mastitis in sheep and goats) in Europe, so this innovative vaccine is now available in several European countries.
The company first launched VIMCO® vaccine for small ruminants in 2014 in Spain, Italy, Greece, Turkey, France, Portugal and Cyprus, and due to its big success, VIMCO is now being launched in other EU countries, including The Netherlands, Belgium and the United Kingdom, at the start of 2018.
VIMCO® is a new tool that allows the prevention of clinical and subclinical mastitis, and therefore allows a more complete and preventive mastitis control programme in sheep and goats.
Most mastitis in small ruminants is caused by Staphylococcus spp and VIMCO® contains a strain of biofilm producing Staphylococcus aureus which confers protection against Staph. aureus and Coagulase Negative Staphylococci (CNS) by controlling biofilm production.
By controlling this staphylococcal mastitis, we can observe an improvement in milk quality and quantity that would impact on the profitability of the farm.
With this new launch of VIMCO® in a growing number of countries, HIPRA strengthens its commitment to the animal production industry to raise healthier and more productive animals, and specifically reinforces its position as the reference in prevention and control of mastitis in the small ruminants’ industry.
